Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
US9750801B2 · kind B2 · utility
7Cited by
3References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 26, 2015 |
| Grant date | Sep 5, 2017 |
| Priority date | — |
| Expiry date | Feb 26, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16171
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.